After Roux-en-Y gastric bypass (RYGB), patients with T2DM and obesity exhibit increased secretion of gut incretin peptides—PYY, GIP, GLP-1, and oxyntomodulin (Oxm)—that reduce food intake, delay gastric emptying, and enhance nutrient uptake [32,33,34]. The gene discussed is GCG; the disease is obesity disorder.